Insider Transactions in Q1 2025 at Janux Therapeutics, Inc. (JANX)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 07
2025
|
David Alan Campbell President and CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.68%
|
$300,000
$60.0 P/Share
|
|
Jan 02
2025
|
Maria Dobek Vice President, Accounting |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+50.0%
|
-
|
|
Jan 02
2025
|
Thomas Di Raimondo Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,000
+15.61%
|
-
|
|
Jan 02
2025
|
Byron Robinson Chief Strategy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
28,000
+50.0%
|
-
|
|
Jan 02
2025
|
David Alan Campbell President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
81,000
+21.37%
|
-
|
|
Jan 02
2025
|
Charles M. Winter Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,000
+22.93%
|
-
|
|
Jan 02
2025
|
Zachariah Mc Iver Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,000
+50.0%
|
-
|
|
Jan 02
2025
|
Andrew Hollman Meyer Chief Business Officer |
SELL
Open market or private sale
|
Direct |
13,334
-2.94%
|
$733,370
$55.64 P/Share
|
|
Jan 02
2025
|
Andrew Hollman Meyer Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,000
+15.86%
|
-
|